{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:06:27Z","timestamp":1780459587451,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T00:00:00Z","timestamp":1266364800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:bold>Objectives<\/jats:bold> To systematically evaluate the clinical characteristics of ADRs caused by Shuanghuanglian Injection (SHLI) and to provide reference for post\u2010market evaluation and clinical application of SHLI.<\/jats:p><jats:p> <jats:bold>Methods<\/jats:bold> We searched electronic databases such as the Chinese National Knowledge Infrastructure (CNKI, 1979\u20132009.9), the Chinese Science and Technology Journal Full\u2010text Database (VIP, 1989\u20132009.9), and the Chinese Biomedical Disc (CBMdisc, 1978\u20132009.9). ADR cases were analyzed according to occurrences categorized. Available data was assessed using the Chi\u2010square test including relative ratios (RR) with 95% confidence intervals (95%CI). Different medicine combinations and comparisons between SHL powder injection and SHL injection were calculated using the statistical software Stata 9.1.<\/jats:p><jats:p> <jats:bold>Results<\/jats:bold> (1) A total of 452 articles were included with a total of 2,799 ADR cases reported. Case reports were the main design type of included literature, which account for 84.51%. According to 31,165 cases of SHLI treatment and 1,013 corresponding ADRs, the incidence of SHLI ADR was calculated as 3.25%. (2) The ratio of male to female in the reported ADR cases was 1.13:1. (3) Allergy to Penicillin, which account for 13.38% of the total cases, was at the top for past allergic history, followed by sulfonamides and asthma (2.68%). (4) In terms of disease treated respiratory disease accounted for 91.75% of all cases of SHLI ADRs, followed by digestive diseases (5.17%), and urinary diseases (1.11%). (5) Penicillins were the most common combination choice with SHLI, and such combination showed higher ADR risk than SHLI used alone (RR = 3.14, 95%CI 2.58 to 3.81). (6) Multiple systems\/organs were involved in SHLI ADRs, and were ranked downwards according to proportion as: skin, digestive system, general reactions, respiratory system, nervous system, cardiovascular system, local reactions, urinary system, hematologic system and others. (7) According to the WHO ADR Classification Criteria, ADR cases were divided into four grades. There were 6.36%, 5.48%, 45.62%, and 2.12% cases of Grade I, II, III, and IV respectively. And the prognoses of the rest 52.42% cases were reported unclearly. (8) All cases of death were caused by allergic shock, except for one, which was caused by myocardial infarction induced by pain at the injection site. The fastest ADR case occurred 1 minute after being injected. (9) There was a remarkable difference (P &lt; 0.05) in the rate of ADR caused by SHLI in power form (2.25%) and as a solution (4.14%).<\/jats:p><jats:p> <jats:bold>Conclusion<\/jats:bold> The clinical manifestations of ADRs caused by SHLI mainly include skin allergic reactions and gastrointestinal reactions. There is an increased risk of ADR induced by combined uses of SHLI and other drugs, especially antibiotics. Compared to the solution, the powder has lower ADR occurrence and higher safety with statistical significance. We propose strengthening management and surveillance on SHLI from manufacturing to application, and improving the level of the risk management for post\u2010market drugs.<\/jats:p>","DOI":"10.1111\/j.1756-5391.2010.01067.x","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T15:13:30Z","timestamp":1266419610000},"page":"18-26","source":"Crossref","is-referenced-by-count":24,"title":["Adverse drug reactions of Shuanghuanglian injection: A systematic review of public literatures"],"prefix":"10.1111","volume":"3","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,25]]},"reference":[{"issue":"6","key":"e_1_2_5_2_2","first-page":"286","article-title":"A Study of the Regulations of the Re\u2010evaluation Skills and Evaluation Modes for Drugs sold on the Market","volume":"12","author":"Yan M","year":"2003","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"key":"e_1_2_5_3_2","unstructured":"The SFDA.Adverse Drug Reaction Information Bulletin 1stissue. [2009\u201312\u20105]. Available from: URL:http:\/\/www.cdr.gov.cn\/gxzy\/ypblfytb\/1373.shtml."},{"key":"e_1_2_5_4_2","unstructured":"The SFDA.Adverse Drug Reaction Information Bulletin. The 22th issue.[2009\u201312\u20105]. Available from: URL:http:\/\/www.cdr.gov.cn\/gxzy\/ypblfytb\/8701.shtml."},{"key":"e_1_2_5_5_2","unstructured":"The SFDA.Emergency Notice from the State Food and Drug Administration to Suspend Use and Sales of Shuanghuanglian Injection manufactured by Jiamusi Branch Wusulijiang Pharmaceutical Company Heilongjiang.[2009\u201312\u20105]. Available from: URL:http:\/\/www.sda.gov.cn\/WS01\/CL0056\/35813.html."},{"key":"e_1_2_5_6_2","unstructured":"The SFDA. Notice from the State Food and Drug Administration to Suspend Use and Sales of Shuanghuanglian Injection Labeled by Manufacturer Duoduo Pharmaceutical Co. Ltd.[2009\u201312\u20105] Available from: URL:http:\/\/www.cdr.gov.cn\/xwdt\/gnxw\/11152.shtml."},{"issue":"1","key":"e_1_2_5_7_2","article-title":"Adverse drug reactions and adverse events of 33 varieties of traditional Chinese medicine injections on the National Essential Drugs List (2004 edition) of China: an overview on published literatures","volume":"3","author":"Wang L","year":"2010","journal-title":"Journal of Evidence-based Medicine"},{"issue":"1","key":"e_1_2_5_8_2","first-page":"54","article-title":"Analysis of 5165 ADRs cases","volume":"1","author":"Zhou J","year":"2004","journal-title":"Chinese Journal of Drug Application and Monitoring"},{"issue":"1","key":"e_1_2_5_9_2","first-page":"41","article-title":"Case report of allergic shock caused by Shuanghuanglian","volume":"13","author":"Zhao DM","year":"1994","journal-title":"Herald of Medicine"},{"issue":"4","key":"e_1_2_5_10_2","first-page":"203","article-title":"An autopsy case of anaphylactic shock cause by Shuanghuanglian Powder","volume":"11","author":"Zhang GH","year":"1996","journal-title":"Chinese Journal of Forensic Medicine"},{"issue":"6","key":"e_1_2_5_11_2","first-page":"366","article-title":"A case report of dead caused by SHL solution","volume":"9","author":"Lei HG","year":"2000","journal-title":"Chinese Journal of Emergency Medicine"},{"issue":"3","key":"e_1_2_5_12_2","first-page":"221","article-title":"Case report of Shuanghuanglian\u2010induced anaphylactic shock","volume":"23","author":"Gu LQ","year":"2001","journal-title":"Journal of Linyi Medical College"},{"issue":"2","key":"e_1_2_5_13_2","first-page":"143","article-title":"A dead case cause by Shuanghuanglian Powder","volume":"15","author":"Li GY","year":"2001","journal-title":"Chinese Pharmaceutical Affairs"},{"issue":"1","key":"e_1_2_5_14_2","first-page":"28","article-title":"One death case of allergic shock caused by intravenous drip of Shuanghuanglian","volume":"25","author":"Chen ZG","year":"2002","journal-title":"Journal of Binzhou Medical University"},{"issue":"2","key":"e_1_2_5_15_2","first-page":"84","article-title":"Two allergic shock cases caused by intravenous drip of Qingkailing and Shuanghuanglian","volume":"17","author":"Du YS","year":"2002","journal-title":"Chinese Journal of Forensic Medcine"},{"issue":"6","key":"e_1_2_5_16_2","first-page":"41","article-title":"Two severe allergic cases of Shuanghuanglian powder","volume":"18","author":"Ju ZL","year":"2002","journal-title":"Shanxi Journal of Traditional Chinese Medicine"},{"issue":"12","key":"e_1_2_5_17_2","first-page":"41","article-title":"One dead case of Shuanghuanglian intravenous injection induced myocardial infarction","volume":"9","author":"Wu YK","year":"2002","journal-title":"Chinese Journal of Rural Medicine and Pharmacy"},{"issue":"3","key":"e_1_2_5_18_2","first-page":"35","article-title":"One death case of intravenous drip of Shuanghuanglian","volume":"9","author":"Zheng ZC","year":"2002","journal-title":"Chinese Journal of Rural Medicine and Pharmacy"},{"issue":"7","key":"e_1_2_5_19_2","first-page":"817","article-title":"Three cases of allergic shock caused by Shuanghuanglian Injection","volume":"11","author":"Ai N","year":"2004","journal-title":"Chinese Journal of Primary Medicine and Pharmacy"},{"issue":"10","key":"e_1_2_5_20_2","first-page":"864","article-title":"One death case caused by Shuanghuanglian Injection","volume":"21","author":"Yin AQ","year":"2007","journal-title":"Chinese Pharmaceutical Affairs"},{"issue":"1","key":"e_1_2_5_21_2","first-page":"136","article-title":"Clinical comparison of ADRS caused by two types of Shuanghuanglian","volume":"3","author":"Li YG","year":"2009","journal-title":"Chinese Journal of Modern Drug Application"},{"issue":"3","key":"e_1_2_5_22_2","first-page":"48","article-title":"Investigation of susceptible population with upper respiratory infection in hospital","volume":"17","author":"Sun BN","year":"2000","journal-title":"Journal of Zhangjiakou Medical College"},{"issue":"3","key":"e_1_2_5_23_2","first-page":"139","article-title":"Data mining study on adverse reaction induced by Shuanghuanglian injection","volume":"5","author":"Wu JR","year":"2008","journal-title":"Chinese Journal of Pharmacovigilance"},{"issue":"10","key":"e_1_2_5_24_2","first-page":"598","article-title":"Analysis and Discussion on Adverse Drug Reaction Events of Traditional Chinese Medicine Injection","volume":"6","author":"Zhang L","year":"2009","journal-title":"Chinese Journal of Pharmacovigilance."},{"issue":"1","key":"e_1_2_5_25_2","first-page":"26","article-title":"Analysis of 288 allergic shock cases caused by TCM injection","volume":"15","author":"Cao HS","year":"2006","journal-title":"Chinese Journal of Pharmacoepidemiology."},{"issue":"2","key":"e_1_2_5_26_2","first-page":"21","article-title":"Investigation of clinical use of Shuanghuanglian Injection between 2001\u20132002 in six provinces and cities","volume":"1","author":"Wu Y","year":"2004","journal-title":"Chinese Journal of Pharmacovigilance."},{"issue":"5","key":"e_1_2_5_27_2","first-page":"638","article-title":"Epidemiological characteristic of anaphylactic shock cased by Shuanghuanglian Injection","volume":"29","author":"Wu JR","year":"2007","journal-title":"Chinese Traditional Patent Medicine."},{"issue":"10","key":"e_1_2_5_28_2","first-page":"12","article-title":"Investigation on the Insoluble Particles of Shuanghuanglian Injection","volume":"5","author":"Yang LJ","year":"2007","journal-title":"China and foreign Medical Journal."},{"issue":"5","key":"e_1_2_5_29_2","first-page":"18","article-title":"Observation on insoluble particles due to compatibility of Shuanghuanglian or Qingkailing Injection with glucose or sodium injection","volume":"19","author":"Yang CP","year":"2004","journal-title":"Journal of Henan University of Chinese Medicine."}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-5391.2010.01067.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-5391.2010.01067.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T02:51:47Z","timestamp":1695783107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-5391.2010.01067.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1756-5391.2010.01067.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-5391.2010.01067.x","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}